Analysis of 129 Cases of Adverse Drug Reactions Induced by Paclitaxel Injection in Patients with Breast Cancer in Our Hospital

Abstract

Abstract: Objective To research the characteristics of adverse drug reactions (ADRs) induced by paclitaxel injection. Methods 129 cases of ADRs induced by paclitaxel injection in our hospital were chosen. The information of patients’ age, drug administration program, time of occurrence, clinical manifestation of ADR were extracted and analyzed. Results In the 129 cases of ADRs, neurological and psychiatric system damage, skin and its appendages damage, liver damage, cardiovascular system damage and systemic injury were mainly involved. Alopecia, deadlimb and transaminase elevation were the most common ADRs. After taking the corresponding measures, these patients basically returned to normal. Conclusion The adverse reactions caused by paclitaxel injection were common and the characteristics were obvious. We should always pay attention to the patients ’ symptoms, give timely and effective treatment, so as to decrease the adverse reactions while exerting better efficacy.

Key words: breast cancer, paclitaxel, adverse reaction, analysis

CLC Number:

LIU Yan-song， ZHAO Kun， ZHANG Guo-qiang. Analysis of 129 Cases of Adverse Drug Reactions Induced by Paclitaxel Injection in Patients with Breast Cancer in Our Hospital[J]. Chinese Journal of Pharmacovigilance, 2016, 13(3): 173-175.

References

[1] 凌霄,王冰,骆小敏,等.紫杉醇注射液化疗的不良反应分析[J].中国医药指南, 2012,10(5):190-191.
[2] 王伟东.紫杉醇注射液致药物不良反应60例分析[J].临床合理用药杂志, 2014,(16):88.
[3] 戴晓雁,柴艳冬,冯晶,等.紫杉醇注射液不良反应的观察和防治措施[C]//第二届肿瘤药学大会论文集. 2009:143-144.
[4] 张秀春.多西紫杉醇联合希罗达治疗乳腺癌肺转移39例临床分析[J].实用肿瘤学杂志, 2008,22(1):26-28.
[5] 梁旭,李惠平,邸立军,等.白蛋白结合型紫杉醇治疗晚期难治性乳腺癌的疗效及安全性分析[J].中国癌症杂志, 2014,(11):836-845.
[6] 桂安萍,凌飞海,郑书楷,等.紫杉醇对早期乳腺癌患者外周血淋巴细胞的影响[J].中国癌症杂志, 2013,(9):737-743.
[7] 赵丽,张姣,付丽,等.乳腺癌细胞Notch1蛋白表达及其与紫杉醇敏感性的关系[J].中国肿瘤临床, 2012,39(9):547-550.
[8] 张龙,王凤玮.紫杉醇用于乳腺癌治疗的应用进展[J].中国医药导报, 2014,11(31):167-169.
[9] 李晓红.紫衫类药物用于老年乳腺癌患者新辅助化疗疗效及不良反应分析[J].实用临床医药杂志, 2013,17(15):74-76.
[10] 师以康,张胜华,黄云虹,等.乳腺癌细胞的HER2过表达降低其对紫杉醇的药物敏感性[J].中国药理学通报,2009,25(4):444-448.
[11] 陈伟,季明华,唐金海,等.乳腺癌紫杉醇耐药的机制[J].中华乳腺病杂志（电子版）, 2015,(4):275-279.
[12] 万冬冬.紫杉醇在乳腺癌治疗的应用[J].中外医学研究,2015,(26):139-140.
[13] 莫非芳.乳腺癌紫杉醇化疗罕见不良反应4例[J].医学信息,2015,(26):360.
[14] 董杨,施建蓉,RichardSalvi,等.抗癌药紫杉醇的神经毒性和耳毒性[J].中华耳科学杂志, 2011,9(3):318-322.
[15] 任杰.乳腺癌CYP1B1表达与紫杉醇耐药的相关性及应用研究[D].天津医科大学, 2013.
[16] 张成文.紫杉醇注射液在乳腺癌患者中的应用研究新进展[J].医药前沿, 2013,(19):143-144.
[17] 易瑛.紫杉醇治疗乳腺癌56例临床观察[J].四川肿瘤防治,2007,20(4):267-269.
[18] 汪进,何放亭,曾志雄,等.紫杉醇诱导人乳腺癌MCF-7细胞周期阻断及凋亡的基因表达谱分析[J].药学学报,
2005,40(12):1099-1104.
[19] 刘淼,王杉,叶颖江,等.乳腺癌中survivin表达及变化与紫杉醇疗效的相关性[J].中国妇产科临床杂志,2008,9(2):131-134.
[20] 施安国,王平全.紫杉醇的毒性研究[J].上海第二医科大学学报,2000,20(2):138-139,160.
[21] 王晶晶,陈兰英.抗癌药物紫杉醇的研究进展[C]//2012环境健康与药物安全性全国学术年会论文集. 2012:533-536.
[22] Yardley DA.Nab-Paclitaxel mechanisms of action anddelivery[J]. J Control Release, 2013, 170(3):365-372.